Nicox Completes U.S. Patient Recruitment for NCX 470 Trial

Nicox SA (FR:ALCOX) has released an update.

Nicox SA has announced the completion of patient recruitment in the U.S. for the Denali Phase 3 trial of NCX 470, a treatment for open-angle glaucoma or ocular hypertension. The trial, which is also ongoing in China, has met its primary efficacy analysis and demonstrated the drug’s superiority at certain timepoints compared to latanoprost. With more than 95% of the target patient number already randomized, Nicox anticipates releasing topline results by the second half of 2025 and submitting a New Drug Application in the U.S. by the first half of 2026.

For further insights into FR:ALCOX stock, check out TipRanks’ Stock Analysis page.